UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Enrolling by invitation
Unique ID issued by UMIN UMIN000047701
Receipt No. R000054386
Scientific Title Exploratory biomarker study on tumor microenvironment using pre-treatment and refractory archival samples of hepatocellular carcinoma
Date of disclosure of the study information 2022/05/10
Last modified on 2022/05/10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Exploratory biomarker study on tumor microenvironment using pre-treatment and refractory archival samples of hepatocellular carcinoma
Acronym Exploratory biomarker study on tumor microenvironment by archival samples of hepatocellular carcinoma
Scientific Title Exploratory biomarker study on tumor microenvironment using pre-treatment and refractory archival samples of hepatocellular carcinoma
Scientific Title:Acronym Exploratory biomarker study on tumor microenvironment by archival samples of hepatocellular carcinoma
Region
Japan

Condition
Condition Unresectable hepatocellular carcinoma
Classification by specialty
Gastroenterology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 Using archival samples (tumor and non-tumor tissue samples, blood samples) of hepatocellular carcinoma patients who received atezolizumab plus bevacizumab or molecular targeted drugs (sorafenib, lenvatinib) in unresectable HCC first-line therapy, we will comprehensively analyze the clinical course and changes in tumor microenvironment and metabolic environment before and after drug treatment. By comparing clinical data such as treatment response, we will explore changes in the tumor microenvironment, including predictors of efficacy and mechanisms of drug resistance.
Basic objectives2 Others
Basic objectives -Others Correlation of the efficacy of atezolizumab plus bevacizumab combination therapy to the tumor microenvironment and metabolic milieu and pre- and post-treatment changes.
Trial characteristics_1 Exploratory
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Correlation between the efficacy of atezolizumab + bevacizumab combination therapy (response, early PD) and tumor microenvironment (PD-1 positive effector T cells, PD-1 positive regulatory T cells, CD36 positive regulatory T cells, angiogenesis and lymphangiogenesis) and metabolic environment (concentration of fatty acids etc.) and pre- and post-treatment changes.
Key secondary outcomes Correlation between the efficacy and etiology of liver (metabolic environment), correlation between atezolizumab + bevacizumab combination therapy and the signature of oncogene expression and pre- and post-treatment changes.
Relation of the efficacy of the molecularly targeted agents lenvatinib and sorafenib to the tumor microenvironment and metabolic environment and pre- and post-treatment changes.
Relation between the efficacy of the molecularly targeted agents lenvatinib and sorafenib before and after treatment and the signatures of oncogene expression in the etiology of liver and changes in the metabolic environment.

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Patients in clinical research approved by the Ethics Review Committee of the Graduate School of Medicine, Chiba University, who have given consent in opt-out form via an information disclosure document, who meet the following eligibility criteria, and who have secondary available archival samples (tumor/non-tumor tissue samples, blood samples).
1) Unresectable hepatocellular carcinoma
2) Receiving lenvatinib, sorafenib, or atezolizumab plus bevacizumab as first-line treatment (excluding hepatic arterial infusion or hepatic arterial chemoembolization)
Key exclusion criteria Patients who do not meet the inclusion criteria.
Target sample size 60

Research contact person
Name of lead principal investigator
1st name Naoya
Middle name
Last name Kato
Organization Chiba University Hospital
Division name Department of Gastroenterology
Zip code 260-8677
Address 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8677, JAPAN
TEL 043-222-7171
Email kato.naoya@chiba-u.jp

Public contact
Name of contact person
1st name Sadahisa
Middle name
Last name Ogasawara
Organization Chiba University Hospital
Division name Department of Gastroenterology
Zip code 260-8677
Address 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8677, JAPAN
TEL 043-222-7171
Homepage URL
Email kato.naoya@chiba-u.jp

Sponsor
Institute Chiba University Hospital
Institute
Department

Funding Source
Organization Chugai Pharmaceutical Co., Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor Chugai Pharmaceutical Co., Ltd.
Name of secondary funder(s)

IRB Contact (For public release)
Organization Ethics Review Committee of the Graduate School of Medicine, Chiba University
Address 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8677, JAPAN
Tel 043-222-7171
Email inohana-rinri@chiba-u.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2022 Year 05 Month 10 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Enrolling by invitation
Date of protocol fixation
2022 Year 01 Month 06 Day
Date of IRB
2021 Year 12 Month 14 Day
Anticipated trial start date
2022 Year 01 Month 06 Day
Last follow-up date
2024 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information Patients in clinical research approved by the Ethics Review Committee of the Graduate School of Medicine, Chiba University, who have given consent in opt-out form via an information disclosure document, who meet the following eligibility criteria, and who have secondary available archival samples (tumor/non-tumor tissue samples, blood samples).
1) Unresectable hepatocellular carcinoma
2) Receiving lenvatinib, sorafenib, or atezolizumab plus bevacizumab as first-line treatment (excluding hepatic arterial infusion or hepatic arterial chemoembolization)

Management information
Registered date
2022 Year 05 Month 10 Day
Last modified on
2022 Year 05 Month 10 Day


Link to view the page
URL(English) https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054386

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.